Jaypirca, the first and only FDA-approved non-covalent (reversible) BTK inhibitor, is a highly selective kinase inhibitor that utilizes a novel non-covalent binding mechanism to extend the benefit of ...
QDs can bind covalently or non-covalently to biomolecules like antibodies, proteins, peptides, aptamer nucleic acids, small molecules, liposomes, lectins, and monosaccharides to identify specific ...